Clinical Study
A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP
Table 2
Frequency of vomiting, nausea, and anorexia at 14 days.
| | | | TJ-43 treated group N (%) | TJ-43 nontreated
group N (%) |
| | Vomiting | Not reported | 7 (87.5) | 6 (60.0) | | Reported | 1 (12.5) | 4 (40.0) | | Nausea | Not reported | 5 (62.5) | 2 (20.0) | | Reported | 3 (37.5) | 8 (80.0) | | Anorexia | Not reported | 5 (37.5) | 3 (30.0) | | Reported | 3 (62.5) | 7 (70.0) |
|
|
